Tenton

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tenton

Property Description
Active ingredient Indometacin (Indomethacin)
Form Capsules, Suppositories, Suspension, Injection
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Alleviates pain, swelling, and fever
Origin Synthetic (Indole derivative)

Tenton is a potent, prescription-only medicinal product containing the single active ingredient, Indometacin (also spelled Indomethacin). It is chemically categorized as a synthetic compound derived from the indole-acetic acid class, distinguishing its structure from other types of NSAIDs. Indometacin is clinically recognized by the medical community for its strength and rapid action compared to many conventional over-the-counter pain relievers. This classification as an NSAID confirms the drug's fundamental identity in managing inflammation.


Composition and Available Pharmaceutical Forms

The core composition of Tenton is the active substance Indometacin, combined with specific excipients necessary to create various pharmaceutical preparations. Indometacin is supplied in multiple forms to allow for different routes of administration, including oral capsules (available as both immediate-release and extended-release formulations), suppositories for rectal use, an oral suspension, and a sterile powder for injection for intravenous administration. This extensive range of forms is widely supported in global regulatory documents, ensuring flexibility in delivery, particularly for patients unable to take medicine orally.


What is the General Purpose of Tenton?

The general purpose of Tenton is to provide reliable symptomatic relief by exerting three distinct physiological actions: providing analgesic relief, reducing anti-inflammatory processes, and generating an antipyretic effect. These actions mean the medicine generally helps to alleviate acute or chronic pain associated with tissue irritation, decrease excessive local swelling or tenderness, and lower an elevated body temperature (fever). For example, it is typically used when pronounced pain relief and inflammation reduction are necessary. This powerful, triple-action profile is the defining characteristic of the drug's therapeutic utility.

What side effects are possible with Tenton?

Possible Side Effects and Safety Information

The information in this section is derived from regulatory safety summaries for the active drug (Tyvaso/treprostinil) associated with the TETON clinical trials, which evaluate its use in certain lung conditions.

Adverse Reaction Profile

Adverse reactions associated with this type of treatment are generally a consequence of its action as a vasodilator and platelet aggregation inhibitor. The most commonly reported side effects typically include: headache, diarrhea, nausea, flushing, and symptoms at the inhalation site.

System-Organ Class Key Adverse Reactions (Regulatory Summary)
Cardiovascular System Symptomatic Hypotension, leading to dizziness or fainting; increased Bleeding Risk due to platelet inhibition.
Respiratory System Risk of acute Bronchospasm (severe airway narrowing), especially in individuals with reactive airway diseases.
Gastrointestinal System Diarrhea, abdominal discomfort, nausea.

Clinically Significant Safety Considerations

  • Serious Hypotension: Because the drug is a systemic vasodilator, it may cause a clinically significant drop in blood pressure, requiring caution, especially in patients who already have low systemic arterial pressure.
  • Population-Specific Risk: Patients with conditions such as asthma, COPD, or other bronchial hyperreactivity are at an elevated risk of developing acute bronchospasm and must be optimally managed for their underlying airway disease prior to and during treatment.
  • Drug Interactions: Co-administration with certain drugs that inhibit the CYP2C8 enzyme (e.g., gemfibrozil) can increase drug exposure, which may lead to an increase in adverse effects. Conversely, co-administration with CYP2C8 inducers (e.g., rifampin) can reduce exposure, potentially limiting effectiveness.

The regulatory safety profile emphasizes that all adverse events, vital signs, and clinical laboratory parameters must be monitored.

Overdose and Emergency Response

The official regulatory documentation for Tenton (Indometacin) overdose describes a profile characterized by significant central nervous system (CNS) and gastrointestinal manifestations.

Documented Overdose Manifestations

Documented CNS signs include severe headache, dizziness, confusion, and unusual drowsiness or dullness. Gastrointestinal symptoms frequently noted are nausea, vomiting (potentially with blood), and stomach pain. Sensory disturbances such as ringing in the ears (tinnitus) and blurred vision are also documented.

Severe Outcomes and Emergency Action

In cases of severe overexposure, the risk of serious, life-threatening outcomes is documented. These include severe CNS events such as seizures and coma, internal complications like acute gastrointestinal bleeding, and the potential for acute renal failure, which may manifest as little or no urine output. Cardiovascular effects, such as high or low blood pressure and increased heart rate, are also recognized.

Regulatory guidance strictly mandates seeking immediate medical help right away upon any suspected overexposure. Individuals must contact emergency services or a Poison Control Center immediately.

Management and Monitoring

As no specific antidote is known for Indometacin toxicity, the official management strategy is defined as symptomatic and supportive treatment. This may include procedures such as gastric lavage, administration of activated charcoal, and continuous monitoring of vital signs and renal function.

Therapeutic Uses of Tenton

Main Therapeutic Uses

Tenton is a medication primarily utilized in the management of chronic conditions characterized by cognitive decline and circulatory disturbances. It is frequently prescribed for the treatment of symptoms associated with organic brain syndrome, which may include memory loss, concentration difficulties, and emotional instability in older adults.

Cognitive Function and Memory

The primary application of Tenton is the symptomatic treatment of cognitive impairment. This includes conditions where patients experience a decline in intellectual performance due to reduced blood flow or degenerative changes in the brain. The medication aims to support cognitive stability and improve the daily functioning of individuals experiencing early-stage dementia or general age-related memory impairment.

Peripheral Circulatory Disorders

Beyond its neurological applications, Tenton is used to address peripheral arterial occlusive disease. It is indicated for the improvement of walking distance in patients who suffer from intermittent claudication, a condition where leg pain occurs during physical activity due to restricted blood flow. By assisting in the management of circulatory health, it helps alleviate the physical limitations caused by these vascular issues.

Vertigo and Tinnitus

Tenton is also indicated for the supportive treatment of inner ear disorders. This includes:

  • Vertigo: Assisting in the management of dizziness and equilibrium disorders resulting from vascular or involutional origins.
  • Tinnitus: Providing a therapeutic option for the management of persistent ringing or buzzing in the ears.

Benefits and Physiological Impact

The benefits of Tenton are centered on its ability to influence blood rheology and metabolic activity within the tissues. The medication works by improving the fluidity of the blood and enhancing the oxygen and glucose uptake in cells that have been compromised by poor circulation.

By supporting these physiological processes, the treatment aims to maintain quality of life, preserve independent living for longer periods in patients with cognitive decline, and increase physical mobility for those with vascular constraints in the extremities.

Eligibility and Restrictions for Use

The use of Tenton (Indometacin) is strictly governed by regulatory eligibility rules defined by government authorities to ensure appropriate use.

Populations That Must Not Use Tenton (Contraindications)

The medicine is absolutely contraindicated for several groups. This includes patients with a known hypersensitivity to indometacin or its components, or those with a history of allergic reactions, asthma, or hives following the use of aspirin or other NSAIDs. Tenton must not be used for pain following Coronary Artery Bypass Graft ( CABG) surgery. It is also contraindicated in late-stage pregnancy (from 30 weeks onward) due to the risk of fetal harm.

Use Limitations and Restrictions

  • Children under 14 years: Safety and efficacy are generally not established for standard oral and rectal formulations. Specific intravenous use is approved only for premature infants to close a Patent Ductus Arteriosus ( PDA).
  • Organ Function: Use must be avoided in patients with severe heart failure or advanced renal disease unless the benefits are determined to outweigh the risks.
  • Older Adults: Use requires greater caution and monitoring due to an increased susceptibility to adverse effects and serious gastrointestinal risk.

What should I know about interactions with other medicines?

Tenton Interactions with other medicines and products

Regulatory documents define several interaction profiles for Tenton (Indometacin) that impact the activity or concentration of co-administered medicines, as well as procedural constraints.

Pharmacodynamic and Systemic Interactions

Interacting Product Category Official Interaction Statement
Antihypertensives (ACE Inhibitors, ARBs, Beta-Blockers) May diminish the antihypertensive effect of these drugs.
Diuretics (Furosemide, Thiazides) Can reduce the natriuretic effect (efficacy) of these medicines.
Drugs that Interfere with Hemostasis (Warfarin, Aspirin, SSRIs/SNRIs) Increases the risk of serious bleeding events.
Other NSAIDs and Analgesic Aspirin Use with other NSAIDs or analgesic doses of aspirin is not generally recommended due to risk of additive adverse effects.

Exposure-Modifying and Other Constraints

Specific Interacting Substance Official Constraint or Outcome
Digoxin, Lithium, Methotrexate Co-administration can increase the serum concentration and prolong the half-life of Digoxin, Lithium, and Methotrexate, respectively.
Mifepristone Must not be used for 8–12 days following Mifepristone administration.
Alcohol May intensify adverse effects, specifically the risk of gastrointestinal blood loss.
CABG Surgery Use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery is contraindicated.

Population-Specific Cautions

The risk of deterioration of renal function is heightened when Tenton is co-administered with ACE Inhibitors or ARBs in elderly patients, those who are volume-depleted, or patients with pre-existing renal impairment.

Mechanism of Action

Tenton's active ingredient, Indometacin, operates by intervening in three distinct mechanistic domains that collectively modulate the signaling pathways associated with inflammation, nociception, and thermogenesis. The substance acts at the molecular level to reduce the activity of specific enzymes and alter signal transduction within targeted pathways.

Indometacin initiates non-selective inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action blocks the early molecular step in the arachidonic acid cascade, preventing the synthesis of prostaglandins and other inflammatory mediators. This suppression directly modifies the inflammatory cascade, resulting in decreased vascular permeability and reduced extracellular fluid leakage.

Centrally, Indometacin inhibits COX activity in the hypothalamus, preventing the PGE2-mediated elevation of the body's thermal set-point. This results in a functional resetting of the thermoregulatory set-point, initiating processes that increase heat dissipation. The drug also limits mediator activity that enhances the sensitivity of peripheral nociceptors, thereby altering the transmission and interpretation of nociceptive signals.

Dosage and Administration Information

Tenton (Indometacin) is administered via multiple official routes, including oral (capsules, suspension), rectal (suppositories), and specialized intravenous (IV) injection. The oral forms are the primary method, with suppositories reserved for situations where oral intake is not feasible, such as at night or for specific patient needs.

The standard administration schedule for adults typically initiates with 25 mg two or three times daily. This regimen is often increased based on clinical protocol to a maintenance dose of 25 mg to 50 mg two to three times daily, not exceeding a general maximum of 150 mg to 200 mg daily in divided doses. An exception to this frequency is the 75 mg extended-release capsule, which is designed for sustained delivery once or twice daily.

For acute, time-limited conditions, treatment is intended to be short-term (e.g., 7 to 14 days), with a plan for a gradual dose reduction after symptom control. In chronic scenarios, the medication is used as part of a long-term plan to manage ongoing symptoms.

Oral administration should occur with food, milk, or an antacid to follow the approved intake condition. Furthermore, the specialized IV powder requires dilution before being administered as an infusion over a specified duration, typically 20 to 30 minutes. Dosage adjustments, such as starting at the lowest possible dose, are generally required for older adults or patients with hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tenton


Evidence for use in Chronic Inflammatory Disorders

Tenton was studied for its use in adult patients experiencing active symptoms related to chronic inflammatory conditions, specifically rheumatoid arthritis and ankylosing spondylitis. Researchers primarily conducted short-term Randomized Controlled Trials (RCTs) and long-term observational studies to explore how symptoms change over time in these conditions. Outcomes monitored included patient-reported pain scales, duration of morning stiffness, and changes in objective measurements related to inflammation.

In these research scenarios, findings describe patterns observed in the studies, where short-term trials documented measurements consistent with initial symptomatic evolution in outcomes related to physical discomfort and stiffness. Studies compared Tenton against other NSAIDs and explored variability in the resulting symptomatic measurements across various study populations.

Evidence for use in Acute Inflammatory Conditions

Research examined Tenton in trials assessing short-term or episodic symptom patterns, such as those related to acute gouty arthritis or localized conditions like bursitis and tendinitis. The primary outcomes monitored were the time until patients reported initial changes in physical discomfort and the time until changes were measured in visible signs of inflammation over periods of one to two weeks.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations, documenting measurements consistent with initial symptomatic evolution in the initial days of the study. The evidence only contributes to understanding the short-term management of acute symptoms.


What is Still Uncertain about Tenton’s Evidence

There is limited information for long-term outcomes related to sustained functional status or influence on disease progression across chronic inflammatory disorders. For very rare indications like certain headache syndromes, evidence quality varies across studies, and sample sizes were modest. Furthermore, in the highly specialized pediatric use for PDA closure, the long-term effects on neurodevelopment are not fully established, and findings were mixed in terms of subsequent changes in major morbidities.

Frequently Asked Questions (FAQ)

Common questions about Tenton (FAQ)


Q: Is there long-term data available on the safety of Tenton?

Regulatory documents indicate that serious risks to the cardiovascular system and the stomach/intestines can occur early in treatment and may increase with the duration of use. These risks are why ongoing monitoring is generally recommended by healthcare providers during treatment. Specific data covering long-term adverse event rates over many years are generally not included in standard patient summaries.


Q: Why do some people stop taking Tenton?

Patients may discontinue Tenton due to common, manageable adverse effects like headache, nausea, or dizziness, or because they have reached their treatment goal. Official warnings also describe serious side effects that could require immediate medical review by a healthcare provider.


Q: What is the purpose of the 'Warnings and Precautions' section for Tenton?

The Warnings and Precautions section in official labeling serves to inform healthcare professionals and patients about serious safety risks that require careful consideration. These risks include cardiovascular events, gastrointestinal bleeding, and kidney problems. This section is key to helping ensure appropriate use and patient safety.


Q: Does Tenton interact with common over-the-counter cold medicines?

Tenton may interact with certain cold medicines, specifically those containing another Non-Steroidal Anti-inflammatory Drug (NSAID) or aspirin. Using Tenton with these products increases the risk of serious side effects, such as bleeding in the stomach or intestines. It is important to check the ingredients of any over-the-counter medicine before use.


Q: Why is Tenton only available by prescription?

Tenton is designated as a prescription-only medicine due to its potency and the significant risks described in its safety profile. Due to these risks, the drug is made available only under the supervision of a healthcare provider.


Q: What is the main reason doctors prescribe Tenton?

According to the official product information, Tenton is prescribed to treat moderate to severe pain, swelling, and stiffness associated with various inflammatory conditions. These conditions typically include rheumatoid arthritis, osteoarthritis, and gouty arthritis.


Q: Can Tenton cause tiredness or make you feel sleepy?

Yes, official labeling lists Central Nervous System (CNS) effects that include dizziness, drowsiness, and confusion as reported side effects. These reported effects are not experienced by every patient.


Q: Does Tenton have a risk of dependence or addiction?

No, the active ingredient in Tenton, Indometacin, is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration. Therefore, it does not carry a risk of dependence or addiction.


Q: Is Tenton a controlled substance?

No, Tenton is a prescription medicine but is not classified as a controlled substance. This means it is not subject to the special legal controls related to drugs with a potential for abuse or dependence.


Q: Is there a generic version of Tenton available?

Yes, the active ingredient in Tenton, Indometacin, is available as a generic product in the U.S. and in other countries. The availability of generic versions is confirmed by official sources like the FDA’s DailyMed database.


Q: Why is Tenton sometimes prescribed along with another medicine?

Tenton may be used alongside other medicines to treat an underlying condition, such as those for blood pressure or heart failure, but these combinations require careful monitoring. Official documents also note that it can affect the concentration of certain other drugs, like Digoxin or Lithium.


Q: Is it normal to feel a change in appetite while on Tenton?

Yes, official labeling lists loss of appetite as a reported adverse reaction. If this symptom is severe or occurs alongside other issues, consultation with a healthcare provider may be required.


Q: Can I drive or operate machinery while taking Tenton?

Official information advises that patients avoid driving a car or operating heavy machinery until they understand how the medication affects them. This caution is due to potential side effects such as dizziness and drowsiness.


Q: Can taking Tenton affect the results of lab tests?

Yes, official product information indicates Tenton can affect laboratory test results, especially those related to kidney function and serum electrolytes. Because of this, providers often recommend monitoring these parameters during treatment.


Q: Is it safe to use Tenton while breastfeeding?

According to regulatory-supported databases, the level of Tenton in breast milk is generally low. While use is sometimes established for infants in specialized situations, some authorities recommend using alternative agents when nursing a newborn or premature infant due to limited long-term data on full-term babies.


Q: Is it true that Tenton can affect heart rhythm?

Yes, official warnings indicate that Tenton can potentially lead to an increase in blood potassium levels, which in turn can cause serious changes in heart rhythm, such as irregular heartbeats. This is a serious event requiring immediate medical review.


Q: What should I do if I think I've taken too much Tenton?

Symptoms of an overdose may include severe headache, dizziness, confusion, extreme tiredness, and seizures. If an overdose is suspected, contacting medical emergency services immediately is advised in official guidelines.


Q: Is Tenton a new drug, or has it been used for a long time?

Tenton, which contains the active ingredient Indometacin, is not a new drug. Public information indicates it was patented in the early 1960s and has been used therapeutically for several decades since its approval.


Q: Do official documents mention weight gain as a side effect of Tenton?

Yes, official labeling specifically lists unexplained or unusual weight gain as a warning sign of fluid retention. This is an observation that is generally recommended to be reported to a healthcare provider, as fluid retention can lead to or worsen conditions like heart failure.


Q: Can Tenton affect my ability to sleep?

Yes, Central Nervous System effects associated with Tenton may include excessive sleepiness or, conversely, trouble staying awake or maintaining a normal sleep pattern.


Q: What is the significance of the Tenton black box warning, if any?

Tenton carries a Boxed Warning—the most serious level of warning required by the FDA—on its label. This warning specifically alerts patients and providers to the risks of serious cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal events (like bleeding and ulcers).

How should Tenton be stored and disposed of?

The official storage and disposal requirements for Tenton depend on its pharmaceutical form.

Storage Conditions and Protection

Form Temperature Requirement
Oral Forms (Capsules) Store at controlled room temperature, 20 C to 25 C (68 F to 77 F) [Source: FDA/DailyMed].
Suppositories Requires refrigerated storage, typically between 2 C and 8 C (36 F to 46 F) [Source: MedlinePlus].

The medicine must be kept in its original, tightly closed container and stored away from heat, moisture, and direct light [Source: MedlinePlus]. It is prohibited to freeze the medicine. After reconstitution, the injection solution must be immediately discarded if not used, as it contains no preservative [Source: FDA Labeling].

Child Safety and Disposal

Keep Tenton out of the reach and sight of children [Source: MedlinePlus]. Do not keep outdated or unused medicine. Disposal should follow a medicine take-back program or official guidelines (e.g., mixing with undesirable material for trash disposal), and the medicine should not be flushed down a toilet or poured down a drain [Source: NIH/MedlinePlus].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tenton found in:

A-Z Index: